-
-
-
-
-
-
-
Epizyme Announces Exercise of $50 Million Option with Royalty Pharma and Highlights Key 2020 Initiatives to Build Long-Term Value
-
-
-
-
-
-
-
Epizyme (EPZM) Announces Positive Pre-NDA Meeting for Tazemetostat for Follicular Lymphoma, Pipeline Updates and Third Quarter 2019 Results
-
-
-
-
-
12,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All